Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

References

• AgadjanyanMGZagorskiKPetrushinaIHumanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyMol Neurodegener20171213328472993
   PubMedGoogle Scholar
• NelsonALDhimoleaEReichertJMDevelopment trends for human monoclonal antibody therapeuticsNat Rev Drug Discov201091076777420811384
   PubMed Web of Science ®Google Scholar
• XuMMPuYWeichselbaumRRFuYXIntegrating conventional and antibody-based targeted anticancer treatment into immunotherapyOncogene201736558559227425593
   PubMed Web of Science ®Google Scholar
• LamerisRde BruinRCGSchneidersFLBispecific antibody platforms for cancer immunotherapyCrit Rev Oncol Hematol201492315316525195094
   PubMed Web of Science ®Google Scholar
• SeckingerADelgadoJAMoserSTarget expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatmentCancer Cell201731339641028262554
   PubMed Web of Science ®Google Scholar
• MooresSLChiuMLBusheyBSA novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumorsCancer Res201676133942395327216193
   PubMed Web of Science ®Google Scholar
• OsadaTPatelSPHammondSAOsadaKMorseMALyerlyHKCEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1Cancer Immunol Immunother201564667768825742933
   PubMed Web of Science ®Google Scholar
• LiLHePZhouCHA novel bispecific antibody, S-Fab, induces potent cancer cell killingJ Immunother201538935035626448579
   PubMed Web of Science ®Google Scholar
• ChengMSantichBHXuHAhmedMHuseMCheungNKSuccessful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumorsOncoimmunology201656e116855727471647
   PubMed Web of Science ®Google Scholar
• FreedmanJDHagelJScottEMOncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsiesEMBO Mol Med2017981067108728634161
   PubMed Web of Science ®Google Scholar
• LiAFXingJYLiLA single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cellsAMB Express2016613227112931
   PubMedGoogle Scholar
• WuXFSerenoAJHuangFFab-based bispecific antibody formats with robust biophysical properties and biological activityMAbs20157347048225774965
   PubMed Web of Science ®Google Scholar
• De MeyerTMuyldermansSDepickerANanobody-based products as research and diagnostic toolsTrends Biotechnol201432526327024698358
   PubMed Web of Science ®Google Scholar
• De VosJDevoogdtNLahoutteTMuyldermansSCamelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its targetExpert Opin Biol Ther20131381149116023675652
   PubMed Web of Science ®Google Scholar
• RozanCCornillonAPetiardCSingle-domain antibody-based and linker-free bispecific antibodies targeting Fc gamma RIII induce potent antitumor activity without recruiting regulatory T cellsMol Cancer Ther20131281481149123757164
   PubMed Web of Science ®Google Scholar
• BannasPHambachJKoch-NolteFNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeuticsFront Immunol20178160329213270
   PubMed Web of Science ®Google Scholar
• ChanLDJAscherDBYadavRConjugation of 10 kDa linear PEG onto trastuzumab Fab’ is sufficient to significantly enhance lymphatic exposure while preserving in vitro biological activityMol Pharm20161341229124126871003
   PubMedGoogle Scholar
• FrechesDPatilHPMachado FrancoMUyttenhoveCHeywoodSVanbeverRPEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’ antibody fragment after pulmonary delivery in three different speciesInt J Pharm20175211–212012928192159
   PubMedGoogle Scholar
• KoussoroplisSJPaulissenGTytecaDPEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tractJ Control Release20141879110024845126
   PubMed Web of Science ®Google Scholar
• AkbarzadehlalehPMirzaeiMMashahdi-KeshtibanMShamsasenjanKHeydariHPEGylated human serum albumin: review of PEGylation, purification and characterization methodsAdv Pharm Bull20166330931727766215
   PubMedGoogle Scholar
• DuncanRThe dawning era of polymer therapeuticsNat Rev Drug Discov20032534736012750738
   PubMed Web of Science ®Google Scholar
• DuncanRPolymer conjugates as anticancer nanomedicinesNat Rev Cancer20066968870116900224
   PubMed Web of Science ®Google Scholar
• PfisterDMorbidelliMProcess for protein PEGylationJ Control Release201418013414924531008
   PubMed Web of Science ®Google Scholar
• AbuchowskiAMcCoyJRPalczukNCvan EsTDavisFFEffect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalaseJ Biol Chem1977252113582358616907
   PubMed Web of Science ®Google Scholar
• AbuchowskiAvan EsTPalczukNCDavisFFAlteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycolJ Biol Chem19772521135783581405385
   PubMed Web of Science ®Google Scholar
• DavisFFCommentary – the origin of pegnologyAdv Drug Deliv Rev200254445745812052708
   PubMed Web of Science ®Google Scholar
• ChapmanAPPEGylated antibodies and antibody fragments for improved therapy: a reviewAdv Drug Deliv Rev200254453154512052713
   PubMed Web of Science ®Google Scholar
• VineKLLobovSChandranVIHarrisNLRansonMImproved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug deliveryPharm Res20153231045105425231010
   PubMed Web of Science ®Google Scholar
• LawrencePBPriceJLHow PEGylation influences protein conformational stabilityCurr Opin Chem Biol201634889427580482
   PubMed Web of Science ®Google Scholar
• HarrisJMChessRBEffect of pegylation on pharmaceuticalsNat Rev Drug Discov20032321422112612647
   PubMed Web of Science ®Google Scholar
• BeharGChamesPTeulonILlama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigenFEBS J20092761443054317
   Web of Science ®Google Scholar
• ZhengCYMaGHSuZGNative PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in 2 characterization of protein PEGylationElectrophoresis200728162801280717702059
   PubMed Web of Science ®Google Scholar
• XingJYLinLMLiJBiHC, a T-cell-engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cellsTransl Oncol201710578078528797938
   PubMed Web of Science ®Google Scholar
• JunttilaTTLiJJohnstonJAntitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsCancer Res201474195561557125228655
   PubMed Web of Science ®Google Scholar
• ZhuZCarterPIdentification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activationJ Immunol19951554190319107636241
   PubMed Web of Science ®Google Scholar
• CignettoSModicaCChiriacoCDual constant domain-Fab: a novel strategy to improve half-life and potency of a met therapeutic antibodyMol Oncol201610693894827103110
   PubMed Web of Science ®Google Scholar
• KangHJKimHJChaSHIsolation of human anti-serum albumin Fab antibodies with an extended serum-half lifeImmunol Lett2016169334026593745
   PubMed Web of Science ®Google Scholar
• ReadTOlkhovRVWilliamsonEDShawAMLabel-free Fab and Fc affinity/avidity profiling of the antibody complex half-life for polyclonal and monoclonal efficacy screeningAnal Bioanal Chem2015407247349735726187320
   PubMed Web of Science ®Google Scholar
• KimHKVan den BosscheJHyunSHThompsonDHAcid-triggered release via dePEGylation of fusogenic liposomes mediated by heterobifunctional phenyl-substituted vinyl ethers with tunable pH-sensitivityBioconjug Chem201223102071207722988941
   PubMed Web of Science ®Google Scholar
• BruunJLarsenTBJolckRIInvestigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cellsInt J Nanomedicine2015105995600826451106
   PubMed Web of Science ®Google Scholar
• DoBHKangHJSongJAGranulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than polyethylene glycol-conjugated GCSFSci Rep20177648028744022
   PubMed Web of Science ®Google Scholar
• FishburnCSThe pharmacology of PEGylation: balancing PD with PK to generate novel therapeuticsJ Pharm Sci200897104167418318200508
   PubMed Web of Science ®Google Scholar
• ReichardEENanaware-KharadeNGonzalezGA3rdThakkarSOwensSMPetersonECPEGylation of a high-affinity anti-(+)methamphetamine single chain antibody fragment extends functional half-life by reducing clearancePharm Res201633122954296627620175
   PubMed Web of Science ®Google Scholar
• MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287
   PubMed Web of Science ®Google Scholar
• SekiyaTYamagishiJGrayJHVPEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8(+) T cell responsesBiomaterials2017137617228544973
   PubMed Web of Science ®Google Scholar